Page 56 - 2020_01-Haematologica-web

Y-H. Ho and S. Méndez-Ferrer et al. stem cell niche is essential for myeloprolifer-
ative neoplasms. Nature. 2014;512(7512):78-
81.
76. Reynaud D, Pietras E, Barry-Holson K, et al.
IL-6 controls leukemic multipotent progeni- tor cell fate and contributes to chronic myel- ogenous leukemia development. Cancer Cell. 2011;20(5):661-673.
77. Pietras EM, Mirantes-Barbeito C, Fong S, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards preco- cious myeloid differentiation at the expense of self-renewal. Nat Cell Biol. 2016;18(6): 607-618.
78. Beaulieu LM, Lin E, Mick E, et al. Interleukin 1 receptor 1 and interleukin 1beta regulate megakaryocyte maturation, platelet activa- tion, and transcript profile during inflamma- tion in mice and humans. Arterioscler Thromb Vasc Biol. 2014;34(3):552-564.
79. Nishimura S, Nagasaki M, Kunishima S, et al. IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol. 2015;209(3):453-466.
80. Grover A, Sanjuan-Pla A, Thongjuea S, et al. Single-cell RNA sequencing reveals molecu- lar and functional platelet bias of aged haematopoietic stem cells. Nat Commun. 2016;7:11075.
81. Frisch BJ, Hoffman CM, Latchney SE, et al. Aged marrow macrophages expand platelet- biased hematopoietic stem cells via inter- leukin1B. JCI Insight. 2019;5.pii:124213.
82. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflamma- tory thrombocytosis. Blood. 2001;98(9): 2720-2725.
83. Yamashita M, Passegue E. TNF-alpha Coordinates hematopoietic stem cell sur- vival and myeloid regeneration. Cell Stem Cell. 2019;25(3):357-372.
84. Sakamaki S, Hirayama Y, Matsunaga T, et al. Transforming growth factor-beta1 (TGF- beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Blood. 1999;94(6):1961-1970.
85. Haas S, Hansson J, Klimmeck D, et al. Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell Stem Cell. 2015;17(4):422-434.
86. Beerman I, Bhattacharya D, Zandi S, et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage poten- tial during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A. 2010;107(12):5465-5470.
87. Mann M, Mehta A, de Boer CG, et al. Heterogeneous responses of hematopoietic stem cells to inflammatory stimuli are altered with age. Cell Rep. 2018;25(11): 2992-3005.
88. Hernandez G, Mills TS, Rabe JL, et al. Pro- inflammatory cytokine blockade attenuates myeloid expansion in a murine model of
rheumatoid arthritis. Haematologica. 2019
May 17. [Epub ahead of print]
89. Pietras EM. Inflammation: a key regulator of
hematopoietic stem cell fate in health and
disease. Blood. 2017;130(15):1693-1698.
90. Mendez-Ferrer S, Battista M, Frenette PS. Cooperation of beta(2)- and beta(3)-adrener- gic receptors in hematopoietic progenitor cell mobilization. Ann N Y Acad Sci.
2010;1192:139-144.
91. Katayama Y, Battista M, Kao WM, et al.
Signals from the sympathetic nervous sys- tem regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407- 421.
92. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature. 2008;452(7186):442-447.
93. Chartier SR, Mitchell SAT, Majuta LA, Mantyh PW. The changing sensory and sympathetic innervation of the young, adult and aging mouse femur. Neuroscience. 2018;387:178-190.
94. Hart EC, Charkoudian N. Sympathetic neu- ral regulation of blood pressure: influences of sex and aging. Physiology (Bethesda). 2014;29(1):8-15.
95. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympa- thetic nerve activity at rest in healthy humans. Hypertension. 1993;21(4):498-503.
96. Veith RC, Featherstone JA, Linares OA, Halter JB. Age differences in plasma norepi- nephrine kinetics in humans. J Gerontol. 1986;41(3):319-324.
97. Ziegler MG, Lake CR, Kopin IJ. Plasma nora- drenaline increases with age. Nature. 1976;261(5558):333-335.
98. Chen S, Du C, Shen M, et al. Sympathetic stimulation facilitates thrombopoiesis by promoting megakaryocyte adhesion, migra- tion, and proplatelet formation. Blood. 2016;127(8):1024-1035.
99. Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res Ther. 2014;16(6):504.
100. Drexler B, Passweg JR, Tzankov A, et al. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myelopro- liferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019;104(4):710-716.
101. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747-1762.
102.Cosentino M, Marino F, Maestroni GJ. Sympathoadrenergic modulation of hematopoiesis: a review of available evi- dence and of therapeutic perspectives. Front Cell Neurosci. 2015;9:302.
103. Casanova-Acebes M, Pitaval C, Weiss LA, et al. Rhythmic modulation of the hematopoi- etic niche through neutrophil clearance. Cell. 2013;153(5):1025-1035.
104.De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-
Gilford progeria. Science. 2003;300(5628):
2055.
105. Eriksson M, Brown WT, Gordon LB, et al.
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syn- drome. Nature. 2003;423(6937):293-298.
106. Merideth MA, Gordon LB, Clauss S, et al. Phenotype and course of Hutchinson- Gilford progeria syndrome. N Engl J Med. 2008;358(6):592-604.
107. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312(5776):1059-1063.
108.Grigoryan A, Guidi N, Senger K, et al. LaminA/C regulates epigenetic and chro- matin architecture changes upon aging of hematopoietic stem cells. Genome Biol. 2018;19(1):189.
109. Heo HR, Chen L, An B, et al. Hormonal reg- ulation of hematopoietic stem cells and their niche: a focus on estrogen. Int J Stem Cells. 2015;8(1):18-23.
110.Stewart MH, Gutierrez-Martinez P, Beerman I, et al. Growth hormone receptor signaling is dispensable for HSC function and aging. Blood. 2014;124(20):3076-3080.
111. Sanchez-Aguilera A, Arranz L, Martin-Perez D, et al. Estrogen signaling selectively induces apoptosis of hematopoietic progen- itors and myeloid neoplasms without harm- ing steady-state hematopoiesis. Cell Stem Cell. 2014;15(6):791-804.
112.Nakada D, Oguro H, Levi BP, et al. Oestrogen increases haematopoietic stem- cell self-renewal in females and during preg- nancy. Nature. 2014;505(7484):555-558.
113.Osorio FG, Navarro CL, Cadinanos J, et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med. 2011;3(106):106ra107.
114. Young K, Borikar S, Bell R, et al. Progressive alterations in multipotent hematopoietic progenitors underlie lymphoid cell loss in aging. J Exp Med. 2016;213(11):2259-2267.
115.Kajimura D, Hinoi E, Ferron M, et al. Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med. 2011;208(4):841-851.
116. Raaijmakers M. Aging of the hematopoietic stem cell niche: an unnerving matter. Cell Stem Cell. 2019;25(3):301-303.
117. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharma- cology of human beta-adrenergic receptor subtypes--characterization of stably trans- fected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004;369 (2):151-159.
118. Deininger MWN, Tyner JW, Solary E. Turning the tide in myelodysplastic/myelo- proliferative neoplasms. Nat Rev Cancer. 2017;17(7):425-440.
119.Li AJ, Calvi LM. The microenvironment in myelodysplastic syndromes: niche-mediat- ed disease initiation and progression. Exp Hematol. 2017;55:3-18.
120. Wang C, Yang Y, Gao S, et al. Immune dys- regulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeu- tic strategies. Crit Rev Oncol Hematol. 2018;122:123-132.
46
haematologica | 2020; 105(1)